SCHEMBL1850785

SCHEMBL1850785

Cc1nn(CCCO)c(C)c1Br

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APAF1 O14727 1/20 0.47
CSNK2A2 P19784 3/20 0.44
CSNK2B P67870 3/20 0.44
CSNK2A1 P68400 3/20 0.44
CSNK2A3 Q8NEV1 3/20 0.44
ALDH1A1 P00352 5/20 0.44
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 3/20 0.43
GAA P10253 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
HPGD P15428 2/20 0.43
HTT P42858 3/20 0.41
AGTR1 P30556 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.37
MAPT P10636 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920216 0.88 APAF1 (0.50) APAF1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL2943809 0.81 HPGD (0.52) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL1855322 0.81 ALDH1A1 (0.50) APAF1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL6417827 0.76 ALDH1A1 (0.58) APAF1ALDH1A1ATMNPSR1GAA
Hydrochloric Acid SCHEMBL6423223 0.74 ALDH1A1 (0.61) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL13117395 0.74 APAF1 (0.45) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL417591 0.74 HTT (0.48) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL16441688 0.73 APAF1 (0.44) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL13177328 0.73 APAF1 (0.50) APAF1ALDH1A1ATMNPSR1GAA
SCHEMBL2588908 0.72 APAF1 (0.50) APAF1ALDH1A1ATMNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA APAF1 1987/4885CSNK2A2 880/4885CSNK2B 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.